Global RNA-based Therapeutics Market is valued at USD 12.4 Bn in 2024 and is predicted to reach USD 22.6 Bn by the year 2034 at a 6.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.
The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered. The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market. The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process.
The Global RNA-Based Therapeutics Market is segmented based on product, type, indication and end-user. By Product segment, the market is divided into Vaccines and Drugs. Whereas, By Type, the market is categorized into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, and Other Therapeutics. The segmentation includes Indication segment which is further classified into Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. The End User segment comprises Hospitals and Clinics, Research Settings.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 12.4 Billion |
| Revenue Forecast In 2034 | USD 22.6 Billion |
| Growth Rate CAGR | CAGR of 6.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product, Type, Indication, End-User and Delivery Mechanism |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.), Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk), Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
RNA-based Therapeutics Market by Product-

RNA-based Therapeutics Market Based on Type-
RNA-based Therapeutics Market Based on Indication-
RNA-based Therapeutics Market Based on End-User-
RNA-based Therapeutics Market By Delivery Mechanism-
RNA-based Therapeutics Market Based on Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.